Search

Your search keyword '"Tavares Da-Silva, Fernanda"' showing total 40 results

Search Constraints

Start Over You searched for: Author "Tavares Da-Silva, Fernanda" Remove constraint Author: "Tavares Da-Silva, Fernanda"
40 results on '"Tavares Da-Silva, Fernanda"'

Search Results

1. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

2. Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study

3. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study

5. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study

7. Immunogenicity and safety of the AS04-HPV-16/18 and HPV-6/11/16/18 human papillomavirus vaccines in asymptomatic young women living with HIV aged 15–25 years: A phase IV randomized comparative study

10. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

14. Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial

19. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans

20. Safety and immunogenicity of a SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in healthy adults: interim findings from a phase 2, randomised, dose-finding, multi-centre study

22. Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: a randomised, placebo-controlled, dose-ranging study

27. Safety of AS03-adjuvanted influenza vaccines: A review of the evidence

28. Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials

29. Safety profile of the adjuvanted recombinant zoster vaccine : Pooled analysis of two large randomised phase 3 trials

30. Spontaneous abortion and ectopic pregnancy: Case definition & guidelines for data collection, analysis, and presentation of maternal immunization safety data

32. Impact of adjuvants on CD4(+) T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial.

33. A Model for Monitoring Spontaneously Reported Medication Errors Using the Adjuvanted Recombinant Zoster Vaccine as an Example

34. Safety, immunogenicity and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae tri-protein vaccine : a phase 1 randomized controlled study in healthy adults.

38. Safety, Immunogenicity, and Antibody Persistence following an Investigational Streptococcus pneumoniaeand Haemophilus influenzaeTriple-Protein Vaccine in a Phase 1 Randomized Controlled Study in Healthy Adults

39. Vaccine Adjuvants: from 1920 to 2015 and Beyond.

40. Safety assessment of adjuvanted vaccines: Methodological considerations.

Catalog

Books, media, physical & digital resources